This combination is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is prescribed for adults and pediatric patients weighing more than 25 kg. The medication is used as a standalone regimen in most cases and helps reduce viral load, strengthen the immune system, and slow disease progression when taken consistently.

This combination works through a multi-targeted approach to block HIV replication. Dolutegravir is an integrase inhibitor that prevents the viral DNA from integrating into the host cell’s genome, a critical step in viral replication. Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing the virus from copying its genetic material. Together, these drugs effectively stop the virus from multiplying, reduce viral load, and help maintain immune function.

This medication is available as a film-coated tablet containing 50 mg dolutegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. The recommended dosage is one tablet taken once daily, with or without food. Patients should take the medication at the same time each day to maintain consistent drug levels. Adherence to the prescribed regimen is essential for effective viral suppression and prevention of drug resistance.

Common side effects include insomnia, headache, fatigue, diarrhea, rash, anxiety, depression, and mild pain. Some patients may also experience allergic skin reactions such as urticaria. Serious side effects, although less common, include bone loss, kidney injury, worsening of hepatitis B infection, immune reconstitution syndrome, lactic acidosis, and liver toxicity or enlargement. Patients should seek immediate medical attention if they experience severe allergic reactions or symptoms such as unusual fatigue, breathing difficulty, or abdominal pain.

This medication should not be used in patients with known hypersensitivity to dolutegravir, emtricitabine, or tenofovir alafenamide. Caution is advised in patients with a history of pancreatitis, liver disease, kidney problems, heart conditions, or bone disorders. Regular monitoring of blood counts, kidney and liver function, and bone health is recommended during treatment. Women of childbearing potential should use effective contraception, as the medication is not recommended during early pregnancy. Breastfeeding should be avoided due to the risk of HIV transmission. Patients should also avoid driving or operating machinery if they feel tired or unwell.

Dolutegravir, emtricitabine, and tenofovir alafenamide provide a modern and effective once-daily treatment option for HIV infection. By combining three powerful antiviral agents into a single tablet, it simplifies therapy and improves adherence. While generally well tolerated, regular monitoring and medical guidance are essential to manage potential side effects. With proper use, this combination plays a key role in long-term HIV management and improving patient quality of life.

This combination should not be taken with certain medications such as dofetilide, as it may cause serious interactions. Always inform your doctor about all medications, supplements, or herbal products you are using.

It is not recommended during early pregnancy, and breastfeeding should be avoided due to the risk of HIV transmission to the baby.

You should contact your doctor immediately if you experience symptoms of allergic reactions, lactic acidosis, or severe side effects such as difficulty breathing or unusual fatigue.

Your doctor may perform tests such as pregnancy tests, hepatitis B screening, kidney function tests, and urine tests before starting treatment.

Symptoms such as severe rash, fever, swelling of the face, breathing difficulty, or skin peeling may indicate hypersensitivity and require immediate medical attention.

Long-term side effects may include kidney problems, bone loss, liver toxicity, worsening hepatitis B, and immune-related conditions, which require regular monitoring.

Symptoms include unusual weakness, muscle pain, breathing difficulty, stomach pain, nausea, dizziness, irregular heartbeat, and feeling cold, especially in the limbs.

Patients with hypersensitivity to its components or certain medical conditions should avoid it unless advised by a healthcare provider.